Safe Surf Rated Back To Home Page Family Friendly Site
About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News Bradford McIntyre
   




GeoVax Labs CSO
Dr. Harriet L. Robinson
to be Honored
at 2011 Georgia Bio (GaBio) Community Awards Ceremony

Recognized for Work on GeoVax's HIV-1 AIDS Vaccine Technology

ATLANTA, Jan. 20, 2011 - Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is one of three recipients of the 2011 Georgia Bio (GaBio) Community Awards. Dr. Robinson will be honored at the GaBio Annual Awards Dinner to be held Thursday, January 20 at Atlanta's Fox Theater.

Dr. Robinson is the developer of GeoVax's HIV-1 AIDS vaccine technology. One of the world's leaders in AIDS vaccine research, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University before joining GeoVax, of which she is a co-founder.

Dr. Robinson's early work with HIV vaccines demonstrated that DNA alone would likely not be sufficient to raise protective immunity for HIV. She combined DNA with protein boosters or live viral-vectored boosters to show that effective control might be achieved through a combination of DNA prime and viral-vectored boosters. It is these vaccines that GeoVax licensed for commercial development and now has in Phase 2 clinical trials. Dr. Robinson received her B.A. from Swarthmore College and her PhD in Microbiology from Massachusetts Institute of Technology.

Commenting on the award, Robert T. McNally, Ph.D., President and CEO of GeoVax, said, "We are delighted that Georgia Bio has seen fit to honor Harriet this year. We at GeoVax have long been aware of her extraordinary talents, and we are lucky to have her on staff as we continue to pursue the development of our preventative and therapeutic HIV vaccines."

Each year, Georgia Bio recognizes individuals, companies or institutions for significant contributions to Georgia's life sciences industry with its GaBio Community Awards. Georgia Bio (www.gabio.org) is a private, non-profit association representing nearly 300 pharmaceutical, biotech and medical device companies, medical centers, universities, research institutes, medical centers, government groups and other business organizations involved in the development of products that improve health and well-being of people animals and the environment.

About GeoVax Labs, Inc. GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV.

Forward-Looking Statements Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act, These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact:
GeoVax Labs, Inc.
Robert T. McNally, President & CEO
678-384-7220


"Reproduced with permission - GeoVax Labs, Inc."

GeoVax Labs, Inc.
www.geovax.com


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik

Copyright © 2003-2017 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS